{
    "nctId": "NCT01509625",
    "briefTitle": "Retrospective Study Assessment Treatment Response Faslodex\u00ae( 500 mg)",
    "officialTitle": "Assessment of Treatment Response With Faslodex\u00ae (500 mg) in Standard Clinical Practice Through a Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Malignant Neoplasm of Breast Stage IV",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 272,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed Informed Consent from patients when possible.\n* In the event of patients who are deceased at the time of inclusion, no signed informed consent will be available; thus, the investigator assumes the responsibility of data protection and confidentiality and of safeguarding the processing of the data.\n* Post-menopausal women.\n* Diagnosed with locally advanced or Metastatic Breast Cancer with histological/cytological confirmation.\n* Documented estrogen receptor positive status for the primary tumour.\n* Patient who, after progression with a previous anti-estrogen treatment, received treatment at some time with fulvestrant (Faslodex\u00ae) at the 500 mg/month and LD-500 dose during the study period.\n\nExclusion Criteria:\n\n* Having received treatment with unapproved or experimental drugs during the study period.\n* Presenting another concomitant cancer other than stage I cervical cancer or cutaneous tumours without lymph node or distant involvement.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}